PLENARY LECTURES

- **Longevity and metabolism**
  Johan Auwerx, Lausanne, Switzerland
- **Salt - a health problem?**
  Tilman Drueke, Amiens, France
- **Stem cells and pluripotency: mechanisms of reprogramming and gene targeting in ES cells and mice**
  George Daley, Cambridge, U.S.A.

MASTERCLASSES

In collaboration with EuroPD

- **Translation of physiology to the clinic**
  - PD drug dosing and pharmacokinetics in peritoneal dialysis: neglected but important
    Jan T. Kielstein, Hannover, Germany
  - Fluid management in PD: where is the fluid?
    Jeroen Kooman, Maastricht, The Netherlands
- **Basic science translated from and to PD**
  - What can nephrologists learn from fibrosis research in PD?
    Janusz Witowski, Poznan, Poland
  - What can nephrologists learn from inflammation and immunology research in PD?
    Donald Fraser, Cardiff, United Kingdom
  - Endothelial glycocalix: a new target of research in PD and uraemia related cardiovascular disease?
    Carmen Vlahu, Amsterdam, The Netherlands

MINI LECTURES

Live imaging of the kidney in health and disease
Andrew Hall, Zurich, Switzerland

New players in mineral homeostasis
René Bindels, Nijmegen, The Netherlands

Angiotensin and tubular salt handling
Laszlo Rosivall, Budapest, Hungary

Renal oxygen sensing and EPO
Kai-Uwe Eckardt, Erlangen, Germany

Insights into uric acid metabolism from GWAS
Anna Koettgen, Freiburg, Germany

Genetic regulation of sodium and potassium transport through WNK kinases
Xavier Jeunemaitre, Paris, France

New insights on calcium disorders
Rajesh V. Thakker, Oxford, United Kingdom

Autosomal dominant polycystic kidney disease: new insights into treatment
Imed Helal, Tunis, Tunisia

The JAK /STAT pathway in renal diseases
Jesus Egido, Madrid, Spain

Vascular and endothelial dysfunction in pre-eclampsia
Kate Bramham, London, United Kingdom

Pulmonary-renal syndrome
Charles Pusey, London, United Kingdom

Peritoneal dialysis in the management of AKI: has it been ignored?
Daniela Ponce, Botucatu, Brazil

Oliguria as a marker of AKI
Wim Van Biesen, Ghent, Belgium

AKI as a side effect of cancer therapy
Sylvie Rottey, Ghent, Belgium

Cross-fertilization between the ERA-EDTA registry and national registries
Benedicte Stengel, Villejuif, France

Where do all these CKD Stage 3 patients disappear and do not progress to CKD 4
Mustafa Arici, Ankara, Turkey

Diabetic nephropathy - from the registry to clinical management
Ivan Rychlik, Prague, Czech Republic

History of the laboratory diagnosis of renal disease
Athanasios Diamandopoulos, Patras, Greece

Immunization against high blood pressure - an update
Tomasz Guzik, Glasgow, United Kingdom

Does renal denervation influence the progression on CKD? Con
Dagmara Hering, Utrecht, The Netherlands

Does renal denervation influence the progression on CKD? Pro
Peter J. Blankestijn, Utrecht, The Netherlands

Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall
Anneleen Pletinck, Ghent, Belgium

Volume - Na - impedance
Adrian Covic, Iasi, Romania

The relationship between endothelial dysfunction and cardiovascular disease in CKD
Mahmut Ilker Yilmaz, Ankara, Turkey

Sodium intake: what is right for people with CKD
Johannes F.E. Mann, Munich, Germany

State of the art of the wearable artificial kidney
Claudio Ronco, Vicenza, Italy

Klotho is a key player in cardiovascular risk during dialysis
Denis Fouque, Lyon, France
Exercise on haemodialysis
Halima Resic, Sarajevo, Bosnia and Herzegovina

Needling strategies and management
Ramon Roca-Tey, Barcelona, Spain

The inflamed uremic phenotype - a mediator of premature aging
Peter Stenvinkel, Stockholm, Sweden

Important trials in transplantation in the last 12 months
Bruno Watschinger, Vienna, Austria

Post transplantation diabetes mellitus – novel pathogenetic factors and therapeutic recommendations
Mads Hornum, Copenhagen, Denmark

SYMPOSIA

Special Symposia

• ERA-EDTA Registry
  - Why do girls with end-stage renal disease wait longer for transplantation than boys?
    Julien Hogan, La Plaine Saint-Denis, France
  - EURODOPPS
    Fergus Caskey, Bristol, United Kingdom
  - Racial disparities in the access to and outcomes of paediatric RRT
    Lidwien Tjaden, Amsterdam, The Netherlands
  - Trends in the epidemiology of renal replacement therapy
    Maria Pippias, Amsterdam, The Netherlands
  - Stage 4 CKD - first results of the EQUAL study
    Moniek Van De Luijtgaarden, Amsterdam, The Netherlands

• Young Nephrologists’ Platform (YNP) - Tomorrow’s nephrology presented by the nephrologists of tomorrow
  - Overview on past and future initiatives of the YNP
    Miklos Z. Molnar, Memphis, U.S.A.
  - Innate and adaptive immunity and the kidney: a pathfinder tale
    Kathrin Effer, Graz, Austria
  - The nephrologist of tomorrow - towards a kidney-omic future?
    Francesco Pesce, London, United Kingdom
  - Emerging factors for predicting adverse outcomes in kidney transplantation: more pieces to the puzzle?
    Maarten Naesens, Leuven, Belgium

• International Practices and Improved Dialysis Outcomes: The DOPPS Program
  - The DOPPS program continues to grow - special highlights
    Ron Pisoni, Ann Arbor, U.S.A.
  - EURODOPPS: First birthday
    Kitty Jager, Amsterdam, The Netherlands
  - KDopps: Improving outcomes in advanced CKD and the transition to dialysis
    Werner Kleophas, Düsseldorf, Germany
  - POOPPS as a unique opportunity for ancillary research: plans for the UK PD catheter study
    Martin Wilkie, Sheffield, United Kingdom

  - Measuring the patient experience: a useful approach to improve dialysis care?
    Hugh Rayner, Birmingham, United Kingdom
  - Panel Discussion

• SYSKID - Prognosis and therapy of diabetic nephropathy: one size does not fit them all
  - The epidemiology of CKD in Europe: implications for healthcare policies
    Kitty J. Jager, Amsterdam, The Netherlands
  - Clinical utility of risk scores/biomarkers to predict progression and outcome in diabetic nephropathy
    Peter Rossing, Gentofte, Denmark
  - Linking biomarkers to pathophysiology and treatment response: a systems biology approach
    Bernd Mayer, Vienna, Austria
  - Enrichment strategies in clinical trials - the road to personalized medicine in nephrology?
    Dick De Zeeuw, Groningen, The Netherlands

• NDT Pearls and Polar Views
  - Clinical science pearls in Nephrology Dialysis and Transplantation in 2013-2014
    Carmine Zoccali, Reggio Calabria, Italy
  - NDT Polar Views
    ABPM for the diagnosis and the monitoring of hypertension in dialysis patients
    Rajiv Agarwal, Indianapolis, USA
    ABPM should be systematically applied in dialysis patients
    Alan Jardine, Glasgow, United Kingdom

• ASN Highlights
  - Acute Kidney Injury
    Ravindra L. Mehta, San Diego, USA
  - Hypertension
    Aldo Peixoto, New Haven, USA
  - General Nephrology/CKD
    Michel Chonchol, Denver, USA

• ISN Session: addressing the global unmet needs for AKI
  - Introduction: ISN AKI 0by25: a human rights case for nephrologists
    Giuseppe Remuzzi, Bergamo, Italy
  - The burden of AKI throughout the world: existing data
    Norbert Lameire, Ghent, Belgium
  - The Global Snapshot: results of a groundbreaking study on AKI
    Ravindra L. Mehta, San Diego, USA
  - Strategies to avoid preventable deaths from AKI in low/middle income countries
    Andrew Lewington, Leeds, United Kingdom
• **What is new and hot in paediatric nephrology: report of ESPN Working Groups activity**
  - Adults and children with renal diseases: a common working area for ESPN and ERA-EDTA
    - **Rosanna Coppo**, Turin, Italy
  - CKD mineral and bone disorder WG
    - **Dieter Haffner**, Hannover, Germany
  - ESPN WG CAKUT/UTI/Bladder dysfunction: news and activities
    - **Stefanie Weber**, Essen, Germany
  - Idiopathic nephrotic syndrome WG
    - **Georges Deschenes**, Paris, France

• **ERA-EDTA & ESH (European Society of Hypertension) Joint Symposium**
  - Multidisciplinary approach of adherence in hypertensive renal patients
    - **Michel Burnier**, Lausanne, Switzerland
  - Ambulatory blood pressure monitoring – the neglected child in nephrology
    - **Josep Redon**, Valencia, Spain
  - Bioimpedance-derived volume assessment for all hypertensives
    - **David Goldsmith**, London, United Kingdom
  - Aldosterone blockade vs. dual renin-angiotensin blockade in patients with resistant hypertension
    - **Speaker to be confirmed**

• **ERA-EDTA & ESC (European Society of Cardiology) Joint Symposium**
  - Valvular heart disease in renal failure patients
    - Natural history of aortic stenosis in renal insufficiency patients
      - **Raphael Rosenhek**, Vienna, Austria
    - TAVI procedure in renal insufficiency patients
      - **Speaker to be confirmed**
    - Valvular calcification in CKD patients
      - **Antonio Bellasi**, Como, Italy
    - The problem of anticoagulation in CKD patients with valvular disease
      - **Jürgen Floege**, Aachen, Germany

• **ERA-EDTA & JSN (Japanese Society of Nephrology) Joint Symposium**
  - Past, present, future: continuous challenge against kidney disease
    - **Seiichi Matsuo**, Nagoya, Japan
  - Development of novel drugs targeting CKD: hypoxia, oxidative stress, and epigenetic
    - **Masaomi Nangaku**, Tokyo, Japan
  - Treatment practice in patients with CKD: results from the GCKD study
    - **Kai-Uwe Eckardt**, Erlangen, Germany
  - CKJ - translational research
    - **Alberto Ortiz**, Madrid, Spain

• **ERA-EDTA & CSN (Chinese Society of Nephrology) Joint Symposium**
  - Diabetic nephropathy: a growing challenge in China
    - **Chuan Ming Hao**, Shanghai, China
  - Diabetic nephropathy in Europe
    - **Carl-Erik Mogensen**, Aarhus, Denmark
  - Management of amyloidosis in China
    - **Xiang Hua Huang**, Nanjing, China
  - Amyloidosis in Europe
    - **Speaker to be confirmed**

• **Hot ethical issues in modern nephrology**
  - When to stop or not to stop renal replacement: do ethic rules offer guidance?
  - Ethical dilemmas in living kidney donation (psychical pressure; bribery)
  - How chronic kidney diseases differ from other chronic diseases from ethical point of view?
  - Ethics and economics of rare diseases

**Late Breaking Clinical Trials**

**The Lancet**

**UK Best Abstracts**

**UK Renal Scientist Award**
Scientific Programme

**Track 1**
**Fluid and electrolytes, tubular transport, physiology**

- **Acid-base regulation and the kidney**
  - Alkali therapy to slow down progression of CKD
    *Thomas H. Hostetter*, Cleveland, U.S.A.
  - New insights into acid-base regulation and the kidney
    *Dominique Eladari*, Paris, France
  - Pathophysiology and clinical diagnosis of distal renal tubular acidosis
    *Robert Unwin*, London, United Kingdom
  - The genetics of acid-base disorders
    *Fiona Karet*, Cambridge, United Kingdom

- **New insights into phosphate handling by kidney, bone and vasculature**
  - Renal handling of phosphate
    *Carsten Wagner*, Zurich, Switzerland
  - FGF23 regulation in bone and kidney
    *Klaus Olgaard*, Copenhagen, Denmark
  - Bone and vasculature crosstalk in health and disease
    *Gérard London*, Fleury-Mérogis, France
  - The role of FGF23 and Klotho in CKD
    *Justine Bacchetta*, Bron, France

- **Channels and transporters: new drug targets**
  - Inhibition of SGLT glucose transporters
    *Volker Vallon*, San Diego, U.S.A.
  - Calcium-sensing and regulation of tubular transport
    *Pascal Houillier*, Paris, France
  - Targeting the vasopressin-aquaporin axis
    *Peter Deen*, Nijmegen, The Netherlands
  - Targeting the water channel AQP1
    *Olivier Devuyst*, Zurich, Switzerland

- **Mechanisms and effects of renal remodelling and ageing**
  - Glomerular epithelial cells in ageing and disease
    *Marcus J. Moeller*, Aachen, Germany
  - Ion transport and epithelial remodelling in the renal distal tubule
    *Johannes Loffing*, Zurich, Switzerland
  - The renin-angiotensin-aldosterone system and the ageing kidney
    *Ariela Benigni*, Bergamo, Italy
  - Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?
    *Alberto Ortiz*, Madrid, Spain

**Track 2**
**Hereditary disorders, development, pregnancy, paediatric nephrology**

- **Storage and traffic disorders**
  - Overview of renal storage disorders
    *Luca Rampoldi*, Milan, Italy
  - Cystinosis
    *William Van’t Hoff*, London, United Kingdom
  - New insights into lysosomal storage disorders
    *Carmine Settembre*, Naples, Italy
  - Renal Fanconi syndromes
    *Robert Kleta*, London, United Kingdom

- **ADPKD**
  - ADPKD: emerging mechanisms in disease pathogenesis
    *Albert Ong*, Sheffield, United Kingdom
  - ADPKD: clinical studies in China
    *Chang Lin Mei*, Shanghai, P.R. China
  - ADPKD: the HALT studies
    *Arlene B. Chapman*, Atlanta, U.S.A.
  - Genetic testing in ADPKD: assessing clinical utility
    *Richard N. Sandford*, Cambridge, United Kingdom

- **From kidney development to kidney regeneration: deciphering developmental cues to engineer kidneys**
  - From human pluripotent stem cells to early nephron
    *Kenji Ōsafune*, Kyoto, Japan
  - From pluripotent stem cells to early collecting system
    *Juan Carlos Izpisúa Belmonte*, La Jolla, U.S.A.
  - Utilization of human nephron stem cells to repair broken kidneys
    *Benjamin Dekel*, Ramat Gan, Israel
  - Renal progenitor cells: a strategy for kidney regeneration
    *Paola Romagnani*, Florence, Italy

- **Growth in pediatric kidney disease**
  - Clinical and epidemiological aspects
    *George S. Reusz*, Budapest, Hungary
  - Growth as the best clinical endpoint to assess CKD-MBD in children?
    *Justine Bacchetta*, Bron, France
  - Bone and growth biomarkers in 2015
    *Dieter Haffner*, Hannover, Germany
  - Growth hormone therapy after two decades of practice
    *Lesley Rees*, London, United Kingdom

- **Haemolytic Uremic Syndrome - a complement disorder**
  - The role of complement in endothelial activation
    *Anna Richards*, Stevenage, United Kingdom
  - Atypical HUS
    *Tim Goodship*, Newcastle Upon Tyne, United Kingdom
  - The glomerular response to shigatoxin in the pathogenesis of D+ HU
    *Moin Saleem*, Bristol, United Kingdom
  - From mutations in complement genes to clinical use of eculizumab
    *Véronique Frêmeaux-Bacchi*, Paris, France
Track 3
Glomerular diseases and general clinical nephrology

- B-cell targeted treatment in glomerular disease
  - B-cell targeting in ANCA-associated vasculitis
    David Jayne, Cambridge, United Kingdom
  - B-cell targeteting in lupus nephritis
    Liz Lightstone, London, United Kingdom
  - B cell targetering in membranous nephropathy
    Piero Ruggenenti, Bergamo, Italy
  - B cell targeting in minimal change disease and FSGS
    Annette Bruchfeld, Stockholm, Sweden

- IgA nephropathy
  - Genetics studies of IgAN reveal links to mucosal pathogens
    Ali G. Gharavi, New York, U.S.A.
  - Modifiable and unmodifiable risk factors for progression of IgA nephropathy
    Rosanna Coppo, Turin, Italy
  - The role of micro-RNA in IgA nephropathy
    Francesco Paolo Schena, Bari, Italy
  - Formation of IgA deposits in Berger’s disease: what we learned from animal models
    Renate Monteiro, Paris, France

- Everyday questions from the glomerulonephritis clinic
  - Managing thrombotic risk in nephrotic syndrome
    Vladimir Tesar, Prague, Czech Republic
  - Approach to the patient with HIV infection referred with proteinuria
    Jeremy Levy, London, United Kingdom
  - Which patients with IgA nephropathy benefit from immunotherapy?
    Jürgen Floege, Aachen, Germany
  - Which patients with diabetes and proteinuria need renal biopsy?
    Loreto Gesualdo, Bari, Italy

- Novel therapeutic approaches in glomerular diseases
  - Biomarker-guided personalized treatment of proteinuria
    Peter Mundel, Boston, U.S.A.
  - Complement targeted therapies in glomerular diseases
    Giuseppe Remuzzi, Bergamo, Italy
  - Current management of lupus nephritis
    Frédéric A. Houssiau, Brussels, Belgium
  - IL-17 as a therapeutic target in crescentic glomerulonephritis
    Ulf Panzer, Hamburg, Germany

- New aspects of podocyte diseases/podocyte stress
  - The challenge and response of podocytes to glomerular hypertension
    Nicole Endlich, Greifswald, Germany
  - The role of mechanical forces in podocyte injury
    Wilhelm Kriz, Mannheim, Germany
  - Ischemic injury of podocyte as a cause of collapsing glomerulopathy
    Surya V. Seshan, New York, U.S.A.
  - Molecular and genetic basis of inherited nephrotic syndrome
    Maddalena Gigante, Foggia, Italy

Track 4
Acute kidney injury and intensive care nephrology

- AKI: general concepts / definition / validation / implementation
  - The health economic burden of AKI
    Donal O’Donoghue, Salford, United Kingdom
  - AKI detection and early intervention: the role of e-alerts
    Mark Devonald, Nottingham, United Kingdom
  - AKI: a true risk or predictor of CKD?
    Paul Stevens, Canterbury, United Kingdom
  - Novel treatments in AKI
    Andrew Lewington, Leeds, United Kingdom

- How to avoid / treat AKI: What do we know? What do we hope?
  - Prevention of AKI, which fluid?
    Donal Reddan, Galway, Ireland
  - Are there differences in the prevention of AKI between younger and older individuals?
    Norbert H. Lameire, Ghent, Belgium
  - Mechanisms of repair after acute kidney injury
    Joseph V. Bonventre, Boston, U.S.A.

- Biomarkers
  - Uremic toxin profile in AKI versus CKD: any therapeutic implications?
    Raymond Vanholder, Ghent, Belgium
  - NGAL vs KIM-1 vs other biomarkers
    Orfeas Liangos, Coburg, Germany
  - The use of biomarkers in septic AKI
    Jill Vanmassenhove, Ghent, Belgium

- RRT and AKI
  - Intermittent haemodialysis and isolated ultrafiltration
    Christophe Vinsonneau, Melun, France
  - Renal replacement therapy in the emerging world
    Valerie A. Luyckx, Zurich, Switzerland
  - Individualizing hemodialysate in various types of AKI
    Francesco Locatelli, Lecco, Italy
  - Should indications be uniform to start RRT in all types of AKI?
    Mehmet Sukru Sever, Istanbul, Turkey
Scientific Programme

Track 5
CKD - epidemiology, prevention, progression, pathophysiology, aging

- **Patient satisfaction**
  - Patient satisfaction: why and how measure it in dialysis patient?
  - **Serge Briançon**, Nancy, France
  - An overview of instruments to measure satisfaction with care in patients on renal replacement therapy
  - **Sabine Van Der Veer**, Manchester, United Kingdom
  - How to implement patient satisfaction in practice patterns evaluation?
  - **Luc Frimat**, Nancy, France
  - Is patient satisfaction a concept that is acceptable in a developing country?
  - **Fayçal Jarraya**, Sfax, Tunisia

- **Aging kidney**
  - Is there a link between foetal programming and the aging kidney?
  - **Kerstin Amann**, Erlangen, Germany
  - Estimating GFR in the elderly in 2014
  - **Christophe Mariat**, Saint-Etienne, France
  - Age and association of kidney measures with mortality and end-stage kidney disease
  - **Stein I. Hallan**, San Diego, U.S.A.
  - Impact of socioeconomic conditions on elderly CKD
  - **Andrzej Wieczek**, Katowice, Poland

- **Proteinuria: therapies beyond renin-angiotensin inhibition**
  - Endothelin Receptor Antagonists to lower proteinuria: looking beyond RAAS intervention
  - **Hiddo J Lambers Heerspink**, Groningen, The Netherlands
  - Can we heal the actin cytoskeleton?
  - **Mario Schiffer**, Hannover, Germany
  - T-type calcium channel inhibitors and proteinuria: a potential renal therapy
  - **Bruce Hendry**, London, United Kingdom
  - Insulin and podocytes
  - **Richard Coward**, Bristol, United Kingdom

- **Uremic toxicities**
  - Uremic toxins and cardiovascular outcomes
  - **Roberto Pecoits-Filho**, Curitiba, Brazil
  - Uremic toxins and renal outcomes
  - **Griet Glorieux**, Ghent, Belgium
  - Uremic toxins and neurological outcomes
  - **Jean-Marc Chillon**, Amiens, France
  - Uremic toxins and gut
  - **Pieter Evenepoel**, Leuven, Belgium

Track 6
Hypertension, diabetes, vascular disease

- **Diabetes, blood pressure and kidney disease**
  - Emerging molecular footprints of diabetic kidney injury
  - **Tobias Huber**, Freiburg, Germany
  - Divergent pathophysiology/clinical course of nephropathy in type 1 and type 2 diabetes
  - **Paola Fioretto**, Padua, Italy
  - Albuminuria in diabetic patients: prognosis and management
  - **Michel Jadoul**, Brussels, Belgium
  - New treatment options to retard progression in CKD patients with diabetes
  - **Luigi Gnudi**, London, United Kingdom

- **Lipoproteins in CKD revisited**
  - Dyslipidaemia in CKD: a risk factor for CV disease and CKD progression?
  - **David Wheeler**, London, United Kingdom
  - Current guidelines and treatment strategies for dyslipidemia in CKD
  - **Christoph Wanner**, Würzburg, Germany
  - Modifications of HDL in chronic kidney disease and their clinical relevance
  - **Marcus Saemann**, Vienna, Austria
  - Lipoproteins, immune system and vascular disease in CKD
  - **Thimoteus Speer**, Homburg/Saar, Germany

- **Renovascular hypertension – when and whom to offer revascularisation?**
  - Current diagnostic algorithms in patients with renal artery stenosis
  - **Andrzej Januszewicz**, Warsaw, Poland
  - Life after ASTRAL and CORAL: where do we go now with renal revascularization for atherosclerotic renal artery stenosis?
  - **Philip A. Kalra**, Salford, United Kingdom
  - Fibromuscular dysplasia - current epidemiology and treatment
  - **Pierre-François Plouin**, Paris, France
  - Cardiovascular complications in patients with renovascular hypertension
  - **Roland E. Schmieder**, Erlangen, Germany

- **Obesity and the kidney**
  - ORG (Obesity Related Glomerulopathy) - does it exist?
  - **Esteban Porrini**, La Laguna, Spain
  - State of the art in weight management
  - **Hermann Toplak**, Graz, Austria
  - Obesity-associated arterial hypertension
  - **Jens Jordan**, Hanover, Germany
  - Renoprotection in obese patient
  - **Francesca Mallamaci**, Reggio Calabria, Italy

- **Vitamin D deficiency in CKD patients**
  - Epidemiology of hypovitaminosis D in CKD patients
  - **Michal Nowicki**, Lodz, Poland
  - Hypovitaminosis D and cardiovascular disease in CKD
  - **Markus Ketteler**, Coburg, Germany
  - Vitamin D, FGF 23 and Klotho - an important triangle in CKD patients
  - **Danilo Fliser**, Homburg/Saar, Germany
  - Treatment with vitamin D – to whom, what and when?
  - **David Goldsmith**, London, United Kingdom
**Scientific Programme**

**Track 7**

**End stage renal disease, dialysis, peritoneal dialysis**

- **CKD-MBD: update 2015**
  - New biomarkers in CKD-MBD
    - **Marc Vervloet**, Amsterdam, The Netherlands
  - The calcium-phosphate product and FGF23
    - **Pablo Antonio Ureña Torres**, Saint-Ouen, France
  - Phosphate binders: which next?
    - **Tilman Drueke**, Amiens, France
  - Which Vitamin D in dialysis patients?
    - **Mario Cozzolino**, Milan, Italy

- **Vascular calcification: what’s new?**
  - Mechanisms of vascular calcification in CKD-evidence for premature ageing?
    - **Ziad Massy**, Paris, France
  - The vitamin D system and the vasculature
    - **Sandro Mazzaferro**, Rome, Italy
  - Should we check for VC in all CKD patients?
    - **Jordi Bover**, Barcelona, Spain
  - Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease
    - **Vincent Brandenburg**, Aachen, Germany

- **Hypercoagulability in ESRD: Myth or reality?**
  - Underlying causes
    - **Jolanta Malyszko**, Bialystok, Poland
  - Risk groups and anticoagulation
    - **Jens Lutz**, Mainz, Germany
  - Pulmonary embolism in chronic kidney disease: a lethal but overlooked disease
    - **Gürbey Ocak**, Utrecht, The Netherlands
  - Vascular access in patients with hypercoagulability
    - **Andrew Davenport**, London, United Kingdom

- **Inflammation in CKD and dialysis patients**
  - Monitoring inflammation in patients on dialysis: why, how, and what else?
    - **Christian Combe**, Bordeaux, France
  - Uremic toxins, inflammation and perturbation of glucose metabolism
    - **Laetitia Koppe**, Montreal, Canada
  - Any relationship between systemic and peritoneal inflammation?
    - **Sylvie Opatrná**, Pilsen, Czech Republic
  - Is EMT of the mesothelium related to an inherent or acquired fast peritoneal transport status and ultrafiltration failure?
    - **Rafael Selgas**, Madrid, Spain

- **Dialysis in the elderly**
  - End-of-life and palliative care in the dialysis setting
    - **Ken Farrington**, Stevenage, United Kingdom
  - Assessing functional status
    - **Eva Topinkova**, Prague, Czech Republic
  - Nutritional characteristics in the elderly dialysis patients
    - **Daniel Teta**, Lausanne, Switzerland
  - The best peritoneal dialysis program for elderly patients
    - **Olof Heimbürger**, Stockholm, Sweden

- **New osmotic agents**
  - Carnitine
    - **Mario Bonomini**, Chieti, Italy
  - GLAD
    - **Raymond T. Krediet**, Amsterdam, The Netherlands
  - Hyperbranched polyglycerol
    - **Asher Mendelson**, London, Canada
  - Glucose polymers
    - **John Leyboldt**, Deerfield, U.S.A.

- **Personalised care and dialysis**
  - Extended-hours hemodialysis: benefits and barriers
    - **Charles Chazot**, Sainte Foy Les Lyon, France
  - Is thrice weekly dialysis adequate for all ESRD patients?
    - **Ercan Ok**, Izmir, Turkey
  - Conservative treatment
    - **Fergus Caskey**, Bristol, United Kingdom
  - Management of advanced CKD in the elderly
    - **Steven J. Rosansky**, Columbia, U.S.A.

**Track 8**

**Transplantation**

- **HLA and non-HLA Antibodies - Avoid them or treat them?**
  - Non-HLA Antibodies - ready to enter the clinic arena?
    - **Magali Girat**, Nantes, France
  - What is the best HLA-desensitisation protocol with regard to long term outcomes?
    - **Ondrej Viklicky**, Prague, Czech Republic
  - Post-transplant DSA – ignore, follow, treat?
    - **Thomas Fehr**, Zurich, Switzerland
  - Kidney exchange and domino-paired transplantation
    - **Willem Weimar**, Rotterdam, The Netherlands

- **Viruses: transplantation in the light of new treatment options**
  - Management of kidney transplant patient with chronic hepatitis C infection
    - **Petar Kes**, Zagreb, Croatia
  - HBV and kidney transplant patients
    - **Fabrizio Fabrizi**, Milan, Italy
  - Treatment of HEV infection after transplantation
    - **Nassim Kamar**, Toulouse, France
  - Update on vaccines for transplant candidates and recipients
    - **Martina Sester**, Homburg/Saar, Germany

- **Age dependent problems in transplantation**
  - Organ age and immune responses
    - **Marian Klinger**, Wroclaw, Poland
  - Transplantation in old recipients: what are the challenges?
    - **Julio Pascual**, Barcelona, Spain
  - Psycho-social problems and adherence in adolescent kidney transplant recipients
    - **Istvan Mucsi**, Toronto, Canada

- **Disease recurrence – are there new treatment strategies on the horizon?**
  - Recurrence of atypical HUS, TMA post renal transplantation
    - **Moglie Donnette-Le Quintrec**, Paris, France
  - Recurrent Focal Glomerulosclerosis
    - **Paolo Cravedi**, New York, U.S.A.
  - Kidney transplantation in primary hyperoxaluria type 1
    - **Pierre Cochat**, Bron, France
CME COURSES

• EURECA-m Working Group
  Updates in cardiorenal cross-talks
  Hypertension, leukocytes and vascular disease
  - Carotid barostimulation in resistant hypertension
    Patrick Rossignol, Vandoeuvre-Les-Nancy, France
  - Cross talk between leukocytes and vessel wall as a source of vascular damage in uremia
    Raymond Vanholder, Ghent, Belgium
  - A new auto-immune disease: hypertension
    Mehmet Kanbay, Istanbul, Turkey

CKD-MBD, adipokines and vascular disease
  - FGF-23: innocent bystander or causative factor in CKD-associated cardiovascular disease?
    Gunnar Heine, Homburg/Saar, Germany
  - The bone-vascular cross-talk and CKD progression: FGF23 and ADMA interaction
    Carmine Zoccali, Reggio Calabria, Italy
  - Role of adipokines in cardiovascular complications in CKD patients – new evidence
    Andrzej J. Wiecek, Katowice, Poland

• CKD-MBD Working Group
  An update on Mineral and Bone Disorders in CKD
  - Introduction
    Mario Cozzolino, Milan, Italy
  First session
  - Evolving insights into the regulation of FGF23 and Klotho
    Marc Vervloet, Amsterdam, The Netherlands
  - New biomarkers in CKD-MBD
    Sandro Mazzaferro, Rome, Italy
  - Calciphylaxis - the power of the dark calcification side
    Vincent Brandenburg, Aachen, Germany
  Second session
  - CaSR in CKD
    Ziad Massy, Paris, France
  - To D or not to D in CKD - is VD treatment unavoidable?
    David Goldsmith, London, United Kingdom
  Third session
  - Adynamic Bone Disease: from bone to disease
    Jordi Bover, Barcelona, Spain
  - Indications of bone biopsy in CKD
    Pablo Antonio Ureña Torres, Saint-Ouen, France
  - Closing remarks
    Mario Cozzolino, Milan, Italy

• DESCARTES Working Group
  Tolerance, minimization, and living donation in 2015
  The race between tolerance and minimization strategies
  - The genetic determinants of acute rejection
    Marc Abramowicz, Brussels, Belgium
  - The genetic determinants of tolerance
    Speaker to be confirmed
  - To what extent can CNI be minimized?
    Klemens Budde, Berlin, Germany
  - Who needs anti-lymphocyte induction therapy in 2015?
    Daniel Abramowicz, Antwerp, Belgium

Hurdles of living-donor kidney transplantation
  - What is the risk of dialysis or death after living donation?
    Umberto Maggiore, Parma, Italy
  - The long road to living donor selection
    Soren Schwartz Sorensen, Copenhagen, Denmark
  - The long road to recipient wait-listing
    Speaker to be confirmed
  - Living kidney donation: future studies
    Geir Mjøen, Oslo, Norway

• Immunonephrology Working Group (IWG)
  Immune mediated renal diseases: news from the ERA-EDTA IWG
  Autoantibodies for diagnosis and prognosis of glomerular diseases
  - Anti-PLA2R antibodies in membranous nephropathy
    Elion Hoxha, Hamburg, Germany
  - New and old auto antibodies in Lupus Nephritis
    Vladimir Tesar, Prague, Czech Republic
  - ANCA in vasculitis new perspectives
    Marten Segelmark, Linköping, Sweden
  - Anti-complement antibodies in MPGN/C3 nephropathy
    Marina Noris, Bergamo, Italy

Clinical endpoints for clinical trials: toward a position paper
  - IgA Nephropathy in the young
    Rosanna Coppo, Turin, Italy
  - IgA Nephropathy in the adult
    Jürgen Floege, Aachen, Germany
  - Lupus Nephritis
    David Jayne, Cambridge, United Kingdom
  - Membranous nephropathy
    Jack F.M. Wetzels, Nijmegen, The Netherlands
**Scientific Programme**

- **EUDIAL Working Group**
  **The rationale for high volume haemodiafiltration**
  - Why do we need convective clearance and different treatment options
    *Speaker to be confirmed*
  - High volume haemodiafiltration in clinical practice
    **Muriel P. Grooteman**, Amsterdam, The Netherlands
  - Clinical outcomes with HDF
    *Speaker to be confirmed*

  **Providing high volume haemodiafiltration in clinical practice**
  - Maintaining water quality for HDF - how much testing is required?
    **Elizabeth Lindley**, Leeds, United Kingdom
  - Why should higher volume HDF improve patient survival?
    **Francesco Locatelli**, Lecco, Italy
  - Is HDF a more expensive treatment compared to other modalities?
    **Antonio Santoro**, Bologna, Italy

- **DIABESITY Working Group**
  **DIABESITY: Diabetes, Obesity and Renal Disease**
  - Connection between obesity, type 2 diabetes and renal disease
    **Bjørn Richelsen**, Aarhus, Denmark
  - Obesity: a risk factor for renal disease, evidence from clinical studies
    **Manuel Praga**, Madrid, Spain
  - Diabetes, obesity and renal disease: lessons from recent clinical trials
    *Speaker to be confirmed*
  - The role of carnosine metabolism in CKD in patients with type-2 diabetes
    *Speaker to be confirmed*
  - New markers of renal disease in obesity and diabetes
    **Radovan Hojs**, Maribor, Slovenia
  - Regression of renal lesions in diabetic and non diabetic renal diseases
    **Giuseppe Remuzzi**, Bergamo, Italy

- **EUTox Working group**
  **Uremic toxicity: the compounds and how to clear them**
  **Part I**
  - Redefining uremic retention solutes and uremic toxins: a novel conceptual framework with therapeutic implications
    *Speaker to be confirmed*
  - Aryl hydrocarbon receptor, a new signaling pathway activated by uremia
    **Stéphane Burtey**, Marseille, France
  - Endothelial microparticles and vascular calcification
    **J. Mariano Rodriguez**, Cordoba, Spain

  **Part II**
  - Dialysis procedures and artificial toxicity in uraemic patients
    **Bernd Stegmayr**, Umeå, Sweden
  - Enhancing dialysis efficacy: dissociating protein-bound uremic retention solutes to increase clearance
    *Speaker to be confirmed*
  - Enhancing dialysis efficacy: modifying pore size and physics to increase removal
    *Speaker to be confirmed*

- **Working Group on Inherited Kidney Disorders (WGIKD)**
  **An update on Inherited Kidney Disorders**
  - Genetic diseases of tubular potassium transport
    **Detlef Bockenhauer**, London, United Kingdom
  - Autosomal Dominant Tubulointerstitial Kidney Disease
    **Olivier Devuyst**, Zurich, Switzerland
  - Clinical trials in ADPKD: where we are and where we go from here
    **Ron T. Gansevoort**, Groningen, The Netherlands
  - Complement-mediated glomerular injury: lessons from animal models
    **Katherine Vernon**, London, United Kingdom
  - Steroid resistant nephrotic syndrome: lessons from the PodoNet registry
    **Franz Schaefer**, Heidelberg, Germany
  - Proteomic and metabolomics analyses in kidney diseases
    **Robert Unwin**, London, United Kingdom

- **Nutrition Working Group**
  **Do renal diseases need a Nutrition Working Group?**
  - Nutritional disorders: also after kidney transplantation
    **Pieter M. Ter Wee**, Amsterdam, The Netherlands
  - Practical screening and assessment of nutritional status in CKD: what, when and by whom?
    **Lina Johansson**, London, United Kingdom
  - The conundrum of salt and protein intake in renal progression
    **Vincenzo Bellizzi**, Salerno, Italy
  - Controlling metabolic acidosis with a healthy diet in CKD patients: feasible?
    **Philippe Chauveau**, Gradignan, France

- **EuroPD Working Group**
  **Basic clinical CME**
  - Physiology and pathophysiology of peritoneal membrane transport
    **Anabela Rodrigues**, Porto, Portugal
  - Peritoneal membrane testing and adequate prescription of peritoneal dialysis regimens in clinical practice
    **Miguel Perez Fontan**, La Coruña, Spain
  - Outcomes on PD: lessons from different cohort and registry studies
    *Speaker to be confirmed*
  - Framing information during pre-dialysis education: actively supporting patients’ decision-making
    **Hilary Bekker**, Leeds, United Kingdom

- **EuroPD Working Group**
  **Advanced level clinical CME**
  - Management of diabetics on PD
    **James Heaf**, Herlev, Denmark
  - CKD-MBD in PD patients
    **Mario Cozzolino**, Milan, Italy
  - Peritoneal dialysis for treatment of congestive heart failure
    *Speaker to be confirmed*
  - Incompliance and adherence: can we change it?
    **Monika Lichodziejewska-Niemierko**, Gdańsk, Poland
Scientific Programme

- **ERBP**
  - Asking the right questions: the guideline on the frail and elderly example
    Evi Nagler, Ghent, Belgium
  - Considering the right outcomes: on hyponatraemia and calcimimetics
    Ionut Nistor, Iasi, Romania
  - Get the guideline to work: the diabetes guideline example
    Davide Bolignano, Reggio Calabria, Italy
  - How systematic is systematic: the vascular access guideline
    Speaker to be confirmed
  - Did you read the guideline?
    Wim Van Biesen, Ghent, Belgium

- **Cross-talk in Renal Epidemiology**
  **First part**
  - Selection bias in renal research
    Carmine Zoccali, Reggio Calabria, Italy
  - Missing data
    Speaker to be confirmed
  - Linkage to achieve big data
    Speaker to be confirmed
  **Second part**
  - IV analysis
    Friedo W. Dekker, Leiden, The Netherlands
  - Using propensity scores to adjust for confounding in medical research
    Stijn Vansteelandt, Ghent, Belgium

- **Rheumatology for nephrologists**
  - Diagnostic approach to the CKD patient with joint pain
    Hans-Joachim Anders, Munich, Germany
  - Diagnosis and treatment of gout in CKD patients
    Speaker to be confirmed
  - What do nephrologists need to know about the auto-inflammatory disorders?
    Helen Lachmann, London, United Kingdom
  - Takayasu arteritis and the kidney
    Justin Mason, London, United Kingdom
  - Why drug monitoring in lupus nephritis
    Nathalie Costedoat-Chalumeau, Paris, France
  - The dilemma: disease activity in lupus nephritis
    Philipp Enghard, Berlin, Germany

- **Perspectives on renal stone disease: a 360° appraisal.**
  A series of case-based presentations on renal stone disease
  - Genetics of calcium balance and hypercalciuria
    Rajesh V. Thakker, Oxford, United Kingdom
  - Nephrology and Urology
    Shabbir Moochhala, London, United Kingdom
  - Clinical Chemistry and renal stone disease
    Gill Rumsby, London, United Kingdom and Marta Lapsley, London, United Kingdom
  - Urology and Nephrology
    Pietro Manuel Ferraro, Rome, Italy

- **Exercise as Medicine in CKD**
  - The new polypill - Exercise training in patients with CKD
    Naomi Clyne, Lund, Sweden
  - Effects of exercise training on functional status and quality of life in CKD
    Evangelia Koufaki, Thessaloniki, Greece
  - Wasting, nutrition and exercise training in CKD
    Adamasco Cupisti, Pisa, Italy
  - Evaluation of functional status before and during exercise training
    Speaker to be confirmed
  - Prescription of exercise training – practical aspects at different stages of CKD
    Rolfdieter Krause, Berlin, Germany

- **Current questions in clinical practice regarding AKI**
  - Sense and nonsense of classifications of AKI
    Wim Van Biesen, Ghent, Belgium
  - Assessment of volume status in patients at ICU
    Jeroen Kooman, Maastricht, The Netherlands
  - Anticoagulation in AKI-RRT: where do we stand in 2015?
    Speaker to be confirmed
  - Dosing regimens in patients with AKI on RRT
    Andrew Lewington, Leeds, United Kingdom

- **Genetics and kidney disease for the beginners**
  - Epigenetics in kidney disease
    Gerjan Navis, Groningen, The Netherlands
  - Micro-RNAs and their importance in kidney disease
    Ariela Benigni, Bergamo, Italy
  - Methodology of GWAS and its application to kidney disease
    Carsten Boeger, Regensburg, Germany
  - Next generation sequencing for research and diagnostics of kidney disease
    Nine V.A.M. Knoers, Utrecht, The Netherlands

- **The Lancet Workshop**

- **Imaging in Nephrology**

**SATELLITE MEETINGS**

- **TNT Renal - A Hands-on Renal Nutrition Course for Healthcare Professionals**
  In collaboration with the International Society of Renal Nutrition and Metabolism (ISRNMT) London, United Kingdom – May 26-27, 2015
  www.renal-nutrition.org

- **4th Update on Fabry Nephropathy – Biomarkers, Progression and Treatment Opportunities**
  Manchester, United Kingdom – June 1-2, 2015